Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Revenue (2023 - 2025)

Historic Revenue for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $3.3 million.

  • Tonix Pharmaceuticals Holding's Revenue rose 1658.4% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 878.58%. This contributed to the annual value of $10.1 million for FY2024, which is 2994.34% up from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Revenue stood at $3.3 million, which was up 1658.4% from $2.0 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Revenue's 5-year high stood at $4.0 million during Q3 2023, with a 5-year trough of $2.0 million in Q2 2025.
  • Moreover, its 3-year median value for Revenue was $2.7 million (2024), whereas its average is $2.9 million.
  • In the last 5 years, Tonix Pharmaceuticals Holding's Revenue tumbled by 3769.75% in 2024 and then soared by 1658.4% in 2025.
  • Tonix Pharmaceuticals Holding's Revenue (Quarter) stood at $3.8 million in 2023, then tumbled by 31.68% to $2.6 million in 2024, then grew by 27.42% to $3.3 million in 2025.
  • Its Revenue stands at $3.3 million for Q3 2025, versus $2.0 million for Q2 2025 and $2.4 million for Q1 2025.